ALCAlcon Inc.
The schedule
- Tue15Dec
Macro valuation reset risk as Alcon's 41.2x P/E remains highly elevated versus the 32.6x industry average.
- Sun7Feb
Q3 results will provide a critical update on whether Alcon's top-line growth (+7.3% YoY) is finally translating into net income recovery.
- Sun9May
Full-year 2026 results and initial 2027 guidance formulation.
- Sun8Aug
First quarter 2027 operating results setting the tone for the fiscal year.
Past
- Tue15Sep
Regulatory milestones and initial commercial rollouts for Alcon's newer presbyopia-correcting and surgical robotics lines.
- Mon17Aug
Actual outcome: Bull
Alcon's stock rallied toward the bull target following a strong Q2 earnings report that surpassed revenue and EPS estimates, driven by equipment and ocular health gains. Upward momentum was further fueled by the company raising its full-year profit forecast for the second consecutive quarter and news that Bill Ackman's Pershing Square initiated a new position in the stock.
Key pipeline data presentations at the American Academy of Ophthalmology annual meeting.
- Sun9Aug
Actual outcome: Bull · $74.25 at outcome
Alcon's Q2 earnings matched expectations, but the stock rallied due to improved guidance and strategic developments. The company raised its 2026 profitability outlook and lowered tariff impact estimates, signaling stronger-than-expected performance. Additionally, Bill Ackman's recent investments in Alcon reinforced investor confidence, driving the price above the bull target.
Alcon's Q2 results will test its premium 41.2x P/E multiple against recent net income declines (-47% YoY).
- Wed15Jul
Actual outcome: Bull · $74.25 at outcome
Alcon's stock rallied 8.4% to surpass the $73.00 bull target, driven by strong business momentum and strategic pipeline developments. A key catalyst was the company's newly announced collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), which bolstered long-term growth prospects and investor confidence alongside the broader 2027 CMS reimbursement outlook.
Release of proposed CMS fee schedules for 2027, impacting specialist reimbursement and surgical volumes.
